- Notice of AGM, Annual Report and Accounts
- Sareum notes publication of SRA737 clinical data
- Second Price Monitoring Extn
- Price Monitoring Extension
- Update on SDC-1801 CTA Application
- Final Results for the Year Ended 30 June 2022
- Update on SRA737
- Sareum notes FDA approval of first TYK2 Inhibitor
- Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
- CTA application to MHRA and Corporate Update
As of last trade
Sareum Holdings PLC (RYH0:FRA) traded at 0.985, 7.07% above its 52-week low of 0.92, set on Nov 24, 2022.
0.92Nov 24 20223.65Dec 01 2021
|Market cap||59.56m GBP|
|EPS (TTM)||-0.0321 |
Data delayed at least 15 minutes, as of Nov 28 2022 08:15 GMT.